Designing Anticancer Peptides by Constructive Machine Learning

ChemMedChem - Tập 13 Số 13 - Trang 1300-1302 - 2018
Francesca Grisoni1,2,3, Claudia S. Neuhaus1,2, Gisela Gabernet1,2, Alex T. Müller1, Jan A. Hiss1, Gisbert Schneider1
1Swiss Federal Institute of Technology (ETH), Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
2these authors contributed equally to this work
3University of Milano-Bicocca, Milano Chemometrics & QSAR Research Group, Department of Earth and Environmental Sciences, 20126 Milan, Italy

Tóm tắt

AbstractConstructive (generative) machine learning enables the automated generation of novel chemical structures without the need for explicit molecular design rules. This study presents the experimental application of such a deep machine learning model to design membranolytic anticancer peptides (ACPs) de novo. A recurrent neural network with long short‐term memory cells was trained on α‐helical cationic amphipathic peptide sequences and then fine‐tuned with 26 known ACPs by transfer learning. This optimized model was used to generate unique and novel amino acid sequences. Twelve of the peptides were synthesized and tested for their activity on MCF7 human breast adenocarcinoma cells and selectivity against human erythrocytes. Ten of these peptides were active against cancer cells. Six of the active peptides killed MCF7 cancer cells without affecting human erythrocytes with at least threefold selectivity. These results advocate constructive machine learning for the automated design of peptides with desired biological activities.

Từ khóa


Tài liệu tham khảo

10.1021/acscentsci.7b00512

10.1021/ci9004089

10.1002/minf.201700111

10.1021/acscentsci.7b00572

10.1002/minf.201700153

10.1002/minf.201501008

T. Mikolov G. Zweig inIEEE Spoken Language Technology Workshop (SLT) 2012 234–239.

A. Graves A. Mohamed G. Hinton inIEEE International Conference on Acoustics Speech and Signal Processing 2013 6645–6649.

10.1021/acs.jcim.7b00414

10.1039/C6MD00376A

10.1093/nar/gku892

10.1371/journal.pone.0181748

10.1016/j.chemphyslip.2011.09.004

D. R.Owen(Helix BioMedix Inc.) US Pat. No. 6875744 B2 2001.

10.1109/T-C.1969.222678

10.1007/s004300050113

10.1016/j.febslet.2005.09.084

10.1074/jbc.M117.805499

10.3389/fphar.2018.00074

10.1016/0196-8858(91)90017-D